Morning Overview on MSN
A new gene-editing treatment just drove back advanced stomach and colon cancers in an early trial — by reprogramming patients’ own immune cells to hunt the tumors
Twelve people whose stomach or colon cancers had defeated every available treatment were infused with their own immune cells, ...
NEW YORK and CAMBRIDGE, England, May 1, 2025 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancers, presented data from a ...
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be effective for patients with metastatic colorectal cancer (CRC) refractory to ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...
Dr. Lou is honored alongside Emma Weston-Dimery, his patient, underscoring Intima's impact on global health NEW YORK and CAMBRIDGE, England, Feb. 11, 2026 /PRNewswire/ -- Intima Bioscience, a clinical ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results